Skip to main content
. Author manuscript; available in PMC: 2025 Aug 15.
Published in final edited form as: Sci Transl Med. 2024 Nov 20;16(774):eadl2184. doi: 10.1126/scitranslmed.adl2184

Fig. 8. TAK-981 treatment ameliorates disease in three mouse models of IBD.

Fig. 8.

(A) DAI, (B) intestinal bleeding, (C) body weight at day 7 of 5-day DSS challenge in mice treated with vehicle or TAK-981 (rTAK) started at day 3 post-DSS and daily for 4 days., (D) DAI, (E) intestinal bleeding, (F) body weight at day 7 of TNBS (150mg/kg) recall instillation in mice treated with vehicle or TAK-981 started 12h before TNBS challenge and daily for 4 days. (G) DAI, (H) intestinal bleeding, (I) body weight, (J) representative macroscopic images, (K) microscopic images, (L) intestinal permeability and peritoneal lavage bacteria, (m) colon inflammatory cytokines at day 7 of oxazolone (1%) (OXA) recall instillation in mice treated with vehicle or TAK-981 started 12h before oxazolone challenge and daily for 4 days. *P<0.05 vs Vehicle (n=4, Two-way ANOVA with Bonferroni’s post-hoc test). *P<0.05 vs Control, #P<0.05 vs OXA (n=4, One-way ANOVA with Bonferroni’s post-hoc test).